Literature DB >> 17143676

Autoimmune-associated hemophagocytic syndrome.

Shunichi Kumakura1, Hiroto Ishikura, Masahiro Kondo, Yohko Murakawa, Junichi Masuda, Shotai Kobayashi.   

Abstract

Hemophagocytic syndrome (HPS) is a clinicopathological condition characterized by the activation of histiocytes with prominent hemophagocytosis in bone marrow and other reticuloendothelial systems. The occurrence of HPS is usually associated with underlying disorders such as infection and lymphoma. Recently, we described patients with autoimmune disease who developed HPS. In these cases there was no evidence of underlying infection and malignancy, and the occurrences of HPS were associated with active autoimmune disease. Based on these observations, we described autoimmune-associated hemophagocytic syndrome (AAHS). This disease entity is becoming better known, and case reports presenting features compatible with clinical AAHS are increasing. Here, we review the clinical aspects, mechanisms, diagnosis, and treatment of AAHS according to our data and that in the literature.

Entities:  

Year:  2004        PMID: 17143676     DOI: 10.1007/s10165-004-0293-6

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  25 in total

1.  Macrophage activation syndrome in a newborn infant born to a mother with autoimmune disease.

Authors:  J H Park; S H Kim; H J Kim; S J Lee; D C Jeong; S Y Kim
Journal:  J Perinatol       Date:  2015-02       Impact factor: 2.521

Review 2.  Prevalence, severity, and pathogeneses of anemia in visceral leishmaniasis.

Authors:  Yasuyuki Goto; Jingjie Cheng; Satoko Omachi; Ayako Morimoto
Journal:  Parasitol Res       Date:  2016-11-07       Impact factor: 2.289

3.  Hemophagocytic syndrome occurring in an adult liver transplant recipient having Still's disease.

Authors:  Sanjaya K Satapathy; M Isabel Fiel; Juan Del Rio Martin; Costica Aloman; Thomas D Schiano
Journal:  Hepatol Int       Date:  2010-10-24       Impact factor: 6.047

4.  Are the 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still's disease?

Authors:  Yoshifumi Tada; Satomi Inokuchi; Akihito Maruyama; Rie Suematsu; Mariko Sakai; Yuri Sadanaga; Nobuyuki Ono; Yojiro Arinobu; Syuichi Koarada
Journal:  Rheumatol Int       Date:  2018-07-26       Impact factor: 2.631

5.  Ankylosing spondylitis presenting with macrophage activation syndrome.

Authors:  Yin-Jun Lou; Jie Jin; Wen-Yuan Mai
Journal:  Clin Rheumatol       Date:  2007-01-18       Impact factor: 2.980

6.  Serum β2-microglobulin level is a useful indicator of disease activity and hemophagocytic syndrome complication in systemic lupus erythematosus and adult-onset Still's disease.

Authors:  Kuninobu Wakabayashi; Shigeko Inokuma; Erika Matsubara; Kae Onishi; Hiromitsu Asashima; Shinichiro Nakachi; Kiyofumi Hagiwara
Journal:  Clin Rheumatol       Date:  2013-03-16       Impact factor: 2.980

Review 7.  Refractory hemophagocytic syndrome in systemic lupus erythematosus successfully treated with intermittent intravenous cyclophosphamide: three case reports and literature review.

Authors:  Yo Ueda; Hiroyuki Yamashita; Yuko Takahashi; Hiroshi Kaneko; Toshikazu Kano; Akio Mimori
Journal:  Clin Rheumatol       Date:  2013-12-18       Impact factor: 2.980

8.  Hemophagocytic syndrome in elderly patients with underlying autoimmune diseases.

Authors:  Rie Tabata; Chiharu Tabata; Makoto Terada; Tomoko Nagai
Journal:  Clin Rheumatol       Date:  2009-01-23       Impact factor: 2.980

9.  Drug-induced liver injury with autoimmune features complicated with hemophagocytic syndrome.

Authors:  Manabu Hayashi; Kazumichi Abe; Hiromichi Imaizumi; Ken Okai; Yukiko Kanno; Atsushi Takahashi; Hiromasa Ohira
Journal:  Clin J Gastroenterol       Date:  2016-04-13

10.  Nationwide survey of hemophagocytic lymphohistiocytosis in Japan.

Authors:  Eiichi Ishii; Shouichi Ohga; Shinsaku Imashuku; Masaki Yasukawa; Hiroyuki Tsuda; Ikuo Miura; Ken Yamamoto; Hisanori Horiuchi; Kenzo Takada; Koichi Ohshima; Shigeo Nakamura; Naoko Kinukawa; Kazuo Oshimi; Keisei Kawa
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.